The ATG101 Knockout HT29 Polyclonal Cells consist of a polyclonal population of HT29 colorectal adenocarcinoma cells engineered via CRISPR/Cas9-mediated disruption of the essential autophagy gene ATG101. This pooled knockout model circumvents clonal selection artifacts and preserves genetic heterogeneity, making it ideal for bulk assays that require representative gene-disruption effects. The CRISPR/Cas9 approach ensures targeted loss of ATG101 function, providing a physiologically relevant platform to dissect autophagy initiation in cancer biology.
Derived from a primary colorectal adenocarcinoma of a 44-year-old female, the HT29 cell line is a widely used epithelial model of human colon cancer. HT29 cells harbor mutations in APC, TP53, and KRAS, reflecting common colorectal oncogenic drivers, and can differentiate under specific conditions. This background offers a clinically relevant context for investigating autophagy-dependent processes in colorectal tumorigenesis, metastasis, and drug response.
ATG101 is an essential autophagy factor that stabilizes the ULK1-ATG13-FIP200 (RB1CC1) complex, the apical kinase module for autophagy initiation. ATG101 directly interacts with ULK1, ATG13, and FIP200, and its presence is required for activation of downstream partners including ATG14, BECN1, and the PIK3C3/VPS34 lipid kinase complex. The ULK1 complex integrates signals from mTORC1, AMPK, and AKT, which respond to nutrient and growth factor status. Upon autophagy induction, phosphorylation of ATG14 and BECN1 promotes phosphatidylinositol 3-phosphate production and recruitment of LC3/GABARAP conjugation systems, leading to autophagosome formation and subsequent degradation of cargo receptors such as p62/SQSTM1.
ATG101 disruption in HT29 cells destabilizes the ULK1-ATG13-FIP200 complex, causing severe autophagy deficiency characterized by reduced LC3B lipidation, impaired autophagic flux, and accumulation of p62/SQSTM1. This loss of autophagy compromises cellular adaptation to nutrient stress and chemotherapeutic challenges. Given the dual role of autophagy in colorectal cancer??suppressive in early stages and pro-survival in established tumors??this model enables precise dissection of autophagy-dependent survival mechanisms and drug resistance pathways in a disease-relevant epithelial setting.
The polyclonal knockout cells are well-suited for mechanistic autophagy studies, high-throughput screening of autophagy modulators, and functional analysis of the ULK1 cascade. Key assays include immunoblotting for LC3B and p62, autophagic flux measurements using lysosomal inhibitors, immunofluorescence detection of LC3 puncta, cell viability under starvation or drug treatment, colony formation, and migration assays. Additionally, the model supports tumor microenvironment studies and in vivo xenograft experiments where genetic heterogeneity may be advantageous. For further information, please contact Ascent Research.
